- Axogen Inc. Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration (FDA) for Avance Nerve Graft®
- Axogen, Inc to Participate at Leerink Partners Healthcare Crossroads Conference
- Axogen, Inc Reports First Quarter 2024 Financial Results
- Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix™
- Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
- Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results
- Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024
- Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
- Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap
- Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2023
More ▼
Key statistics
On Thursday, AxoGen Inc (AXGN:NAQ) closed at 6.11, 77.10% above the 52 week low of 3.45 set on Nov 01, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6.21 |
---|---|
High | 6.21 |
Low | 6.02 |
Bid | 2.45 |
Offer | 9.71 |
Previous close | 6.11 |
Average volume | 226.78k |
---|---|
Shares outstanding | 43.70m |
Free float | 39.87m |
P/E (TTM) | -- |
Market cap | 267.03m USD |
EPS (TTM) | -0.4943 USD |
Data delayed at least 15 minutes, as of May 23 2024 21:00 BST.
More ▼